Shots:
- J&J has reported subgroup analysis from P-III (ICONIC-LEAD) trial assessing icotrokinra (QD, PO; n=456) vs PBO (n=228) in 684 adolescents & adults with mod. to sev. plaque PsO
- At Wk. 16, 84.1% adolescent achieved IGA 0/1 vs 27.3%, & 70.5% vs 13.6% reached PASI 90. By Wk. 24, 86.4% achieved IGA 0/1, 88.6% reached PASI 90, plus 75% had completely clear skin (IGA 0), with 63.6% achieving PASI 100; data was presented at WCPD 2025
- Icotrokinra (JNJ-2113) is being evaluated in ICONIC Program: ICONIC-TOTAL (vs PBO) for PsO, ICONIC-ADVANCE 1 & 2 (vs PBO & Sotyktu) & ICONIC-ASCEND (vs PBO & Stelara) for mod. to sev. PsO, plus ICONIC-PsA 1 & 2 (vs PBO) for active PsA
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related News:- Johnson & Johnson Reports P-III (Vivacity-MG3) Trial Data of Nipocalimab for Generalized Myasthenia Gravis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
